DNLI: Denali Therapeutics Inc

DNLI News

• 18:23 DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
• 21:05 Denali Therapeutics announces board and leadership changes
• 12:21 デナリ・セラピューティクス株、FDAの延期にもH.C.ワインライトは買い推奨を維持
• 12:17 Denali Therapeutics stock faces FDA delay as H.C. Wainwright maintains Buy rating
• 14:43 FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate - Denali Therapeutics (NASDAQ:DNLI)
• 12:23 FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
• 11:55 スティーフェル、デナリ・セラピューティクスの買い推奨を維持、FDA審査延期も
• 11:54 Stifel reiterates Buy rating on Denali Therapeutics stock amid FDA review delay
• 20:06 FDAがデナリ社のハンター症候群治療薬の審査期間を延長
• 20:05 FDA extends review of Denali’s Hunter syndrome treatment
• 00:21 Tracking Baker Brothers Portfolio – Q2 2025 Update
• 15:30 Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
• 06:31 Denali Therapeutics Inc. (DNLI) Morgan Stanley 23rd Annual Global Healthcare Transcript
• 11:46 Cantor Fitzgerald reiterates Overweight rating on Denali Therapeutics stock
• 00:40 Denali therapeutics’ Ho Carole sells $52k in stock
• 00:37 Denali Therapeutics COFO Schuth sells $39884 in stock
• 12:18 DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
• 13:32 Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
• 12:55 Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
• 15:37 William Blair reiterates Outperform rating on Denali stock after BLA acceptance
• 15:06 Denali Therapeutics stock gains as FDA grants priority review for Hunter syndrome drug
• 12:10 FDA accepts priority review for Denali’s Hunter syndrome therapy
• 20:08 Denali Therapeutics stock poised for catalyst as FDA decision nears
• 01:14 Tracking Baker Brothers Portfolio – Q1 2025 Update